Epigenetics and immunotherapy: The current state of play

Molecular Immunology

Volumn 87, Issue , 2017, Pages 227-239

  Dunn, Jennifer ^a   Rao, Sudha ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Combination therapy; DNA methyltransferase inhibitors; Epigenetics; Histone deacetylase inhibitors; Immune checkpoint blockade; Immunotherapy

Indexed keywords

BROMODOMAIN INHIBITOR; INTERFERON; METHYLTRANSFERASE INHIBITOR; OXYGENASE INHIBITOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CANCER PATIENT; CELL CYCLE CHECKPOINT; EPIGENETICS; EPITHELIAL CANCER CELL LINE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; ANIMAL; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; NEOPLASMS; PROCEDURES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85019207258     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2017.04.012     Document Type: Review

References (138)

1. Adeegbe, D.O.F., Freeman, G.J., Wong, K.K., BET bromodomain inhibition synergizes with immune checkpoint blockade to facilitate anti-tumor response in a murine model of non-small cell lung cancer harboring KRAS mutation. J. Immunol., 196(Supplement 1), 2016 74.10.
2. Ahearne, M.J., Allchin, R.L., Fox, C.P., Wagner, S.D., Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. Br. J. Haematol. 166 (2014), 326–335.
3. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A., Armand, P., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372 (2015), 311–319.
4. Armeanu, S., Bitzer, M., Lauer, U.M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., Steinle, A., Salih, H.R., Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65 (2005), 6321–6329.
5. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W.H., Brasnu, D.F., Tartour, E., Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 (2006), 465–472.
6. Bao, L., Dunham, K., Lucas, K., MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol. Immunother. 60 (2011), 1299–1307.
7. Barry, M., Bleackley, R.C., Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2 (2002), 401–409.
8. Bartova, E., Pachernik, J., Harnicarova, A., Kovarik, A., Kovarikova, M., Hofmanova, J., Skalnikova, M., Kozubek, M., Kozubek, S., Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. J. Cell Sci. 118 (2005), 5035–5046.
9. Bartova, E., Krejci, J., Harnicarova, A., Galiova, G., Kozubek, S., Histone modifications and nuclear architecture: a review. J. Histochem. Cytochem. 56 (2008), 711–721.
10. Bates, G.J., Fox, S.B., Han, C., Leek, R.D., Garcia, J.F., Harris, A.L., Banham, A.H., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24 (2006), 5373–5380.
11. Berghuis, D., Schilham, M.W., Vos, H.I., Santos, S.J., Kloess, S., Buddingh, E.P., Egeler, R.M., Hogendoorn, P.C., Lankester, A.C., Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin. Sarcoma Res., 2, 2012, 8.
12. Bingle, L., Brown, N.J., Lewis, C.E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 (2002), 254–265.
13. Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-Cell non-Small-Cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
14. Bukur, J., Jasinski, S., Seliger, B., The role of classical and non-classical HLA class I antigens in human tumors. Semin. Cancer Biol. 22 (2012), 350–358.
15. Chiappinelli, K.B., Zahnow, C.A., Ahuja, N., Baylin, S.B., Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76 (2016), 1683–1689.
16. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N.S., Cope, L.M., Snyder, A., Makarov, V., Budhu, S., Slamon, D.J., Wolchok, J.D., Pardoll, D.M., Beckmann, M.W., Zahnow, C.A., Merghoub, T., Chan, T.A., Baylin, S.B., Strick, R., Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell, 164, 2016, 1073.
17. Comes, A., Rosso, O., Orengo, A.M., Di Carlo, E., Sorrentino, C., Meazza, R., Piazza, T., Valzasina, B., Nanni, P., Colombo, M.P., Ferrini, S., CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176 (2006), 1750–1758.
18. Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jager, E., Seliger, B., Maio, M., 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 8 (2002), 2690–2695.
19. Correale, P., Rotundo, M.S., Del Vecchio, M.T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K.Y., Licchetta, A., Mannucci, S., Loiacono, L., Tassone, P., Francini, G., Tagliaferri, P., Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 33 (2010), 435–441.
20. Covre, A., Coral, S., Di Giacomo, A.M., Taverna, P., Azab, M., Maio, M., Epigenetics meets immune checkpoints. Semin. Oncol. 42 (2015), 506–513.
21. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M.L., Knutson, K.L., Chen, L., Zou, W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
22. Dissemond, J., Busch, M., Kothen, T., Mors, J., Weimann, T.K., Lindeke, A., Goos, M., Wagner, S.N., Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Lett. 203 (2004), 225–231.
23. Dolan, D.E., Gupta, S., PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 21 (2014), 231–237.
24. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., Lennon, V.A., Celis, E., Chen, L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
25. Dunn, J., McCuaig, R., Tu, W.J., Hardy, K., Rao, S., Multi-layered epigenetic mechanisms contribute to transcriptional memory in T lymphocytes. BMC Immunol., 16, 2015, 27.
26. Espada, J., Esteller, M., Epigenetic control of nuclear architecture. Cell. Mol. Life Sci. 64 (2007), 449–457.
27. Esteller, M., Epigenetics in cancer. N. Engl. J. Med. 358 (2008), 1148–1159.
28. FDA, FDA Approves New, Targeted Therapy for Bladder Cancer. 2016 (Accessed 10 October 2016) http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm.
29. Fedorova, E., Zink, D., Nuclear architecture and gene regulation. Biochim. Biophys. Acta 1783 (2008), 2174–2184.
30. Fiegler, N., Textor, S., Arnold, A., Rolle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens-Harig, M., Cerwenka, A., Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122 (2013), 684–693.
31. Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Nicolay, H.J., Sigalotti, L., Maio, M., The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol. Oncol. 5 (2011), 164–182.
32. Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., Yao, J., Jin, L., Wang, H., Yang, Y., Fu, Y.X., Wang, F.S., Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132 (2007), 2328–2339.
33. Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
34. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., Chen, P.L., Hwu, P., Allison, J.P., Futreal, A., Wargo, J.A., Sharma, P., Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404 (e399).
35. Gimenez, J., Montgiraud, C., Pichon, J.P., Bonnaud, B., Arsac, M., Ruel, K., Bouton, O., Mallet, F., Custom human endogenous retroviruses dedicated microarray identifies self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. Nucleic Acids Res. 38 (2010), 2229–2246.
36. Gollob, J.A., Sciambi, C.J., Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin. Cancer Res. 13 (2007), 5219–5225.
37. Goswami, C.J.S., Zhao, H., Zhang, X., Sharma, P., Epigenetic changes in T cells in response to immune checkpoint blockade. [abstract]. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 Apr 16–20; New Orleans, LA Philadelphia (PA): AACR;, Cancer Res, 2016, 76 (Abstract nr 4026).
38. Groh, S., Schotta, G., Silencing of endogenous retroviruses by heterochromatin. Cell Mol Life Sci, 2017, 1–11, 10.1007/s00018-017-2454-8.
39. Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., Veys, I., Haibe-Kains, B., Singhal, S.K., Michiels, S., Rothe, F., Salgado, R., Duvillier, H., Ignatiadis, M., Desmedt, C., Bron, D., Larsimont, D., Piccart, M., Sotiriou, C., Willard-Gallo, K., CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123 (2013), 2873–2892.
40. Han, H., Yang, X., Pandiyan, K., Liang, G., Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells. PLoS One, 8, 2013, e75136.
41. Heninger, E., Krueger, T.E., Lang, J.M., Augmenting antitumor immune responses with epigenetic modifying agents. Front. Immunol., 6, 2015, 29.
42. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., Kohrt, H.E., Horn, L., Lawrence, D.P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P.S., Mellman, I., Chen, D.S., Hodi, F.S., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
43. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbe, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
44. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., Pelicci, P.G., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005), 71–76.
45. Ishibashi, K., Kumai, T., Ohkuri, T., Kosaka, A., Nagato, T., Hirata, Y., Ohara, K., Oikawa, K., Aoki, N., Akiyama, N., Sado, M., Kitada, M., Harabuchi, Y., Celis, E., Kobayashi, H., Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology, 5, 2016, e1169356.
46. James, S.R., Link, P.A., Karpf, A.R., Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25 (2006), 6975–6985.
47. Jazirehi, A.R., Nazarian, R., Torres-Collado, A.X., Economou, J.S., Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Am. J. Clin. Exp. Immunol. 3 (2014), 43–56.
48. Jia, Y., Zeng, Z., Li, Y., Li, Z., Jin, L., Zhang, Z., Wang, L., Wang, F.S., Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PLoS One, 10, 2015, e0117458.
49. Jones, P.A., Baylin, S.B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002), 415–428.
50. Jones, P.A., Takai, D., The role of DNA methylation in mammalian epigenetics. Science 293 (2001), 1068–1070.
51. Juergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., Lee, B., Tsai, S., Delgado, I.E., Rudek, M.A., Belinsky, S.A., Herman, J.G., Baylin, S.B., Brock, M.V., Rudin, C.M., Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1 (2011), 598–607.
52. Kagoya, Y., Nakatsugawa, M., Yamashita, Y., Ochi, T., Guo, T., Anczurowski, M., Saso, K., Butler, M.O., Arrowsmith, C.H., Hirano, N., BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126 (2016), 3479–3494.
53. Kaklamanis, L., Leek, R., Koukourakis, M., Gatter, K.C., Harris, A.L., Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55 (1995), 5191–5194.
54. Kassiotis, G., Stoye, J.P., Immune responses to endogenous retroelements: taking the bad with the good. Nat. Rev. Immunol. 16 (2016), 207–219.
55. Khan, A.N., Gregorie, C.J., Tomasi, T.B., Histone deacetylase inhibitors induce TAP, LMP Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57 (2008), 647–654.
56. Kim, K., Skora, A.D., Li, Z., Liu, Q., Tam, R.L., Diaz, L.A. Jr., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Zhou, S., Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 11774–11779.
57. Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
58. Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., Asahina, H., Jones, R.E., Kulkarni, M.M., Kuraguchi, M., Palakurthi, S., Fecci, P.E., Johnson, B.E., Janne, P.A., Engelman, J.A., Gangadharan, S.P., Costa, D.B., Freeman, G.J., Bueno, R., Hodi, F.S., Dranoff, G., Wong, K.K., Hammerman, P.S., Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 7, 2016, 10501.
59. Krishnadas, D.K., Shusterman, S., Bai, F., Diller, L., Sullivan, J.E., Cheerva, A.C., George, R.E., Lucas, K.G., A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol. Immunother. 64 (2015), 1251–1260.
60. Lanier, L.L., NK cell recognition. Annu. Rev. Immunol. 23 (2005), 225–274.
61. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B., Maio, M., Marquez-Rodas, I., McArthur, G.A., Ascierto, P.A., Long, G.V., Callahan, M.K., Postow, M.A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L.M., Horak, C., Hodi, F.S., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
62. Leffers, N., Gooden, M.J., de Jong, R.A., Hoogeboom, B.N., ten Hoor, K.A., Hollema, H., Boezen, H.M., van der Zee, A.G., Daemen, T., Nijman, H.W., Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58 (2009), 449–459.
63. Li, B., Carey, M., Workman, J.L., The role of chromatin during transcription. Cell 128 (2007), 707–719.
64. Li, H., Chiappinelli, K.B., Guzzetta, A.A., Easwaran, H., Yen, R.W., Vatapalli, R., Topper, M.J., Luo, J., Connolly, R.M., Azad, N.S., Stearns, V., Pardoll, D.M., Davidson, N., Jones, P.A., Slamon, D.J., Baylin, S.B., Zahnow, C.A., Ahuja, N., Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5 (2014), 587–598.
65. Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., Adema, G.J., The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138 (2013), 105–115.
66. Liu, Y., Komohara, Y., Domenick, N., Ohno, M., Ikeura, M., Hamilton, R.L., Horbinski, C., Wang, X., Ferrone, S., Okada, H., Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol. Immunother. 61 (2012), 789–801.
67. Liu, X.S., Ye, M., Collins, M., Favata, R., Yang, M., Diamond, G., Dostalik, M., Lo, V., He, Y., Wu, C., Combs, L., Yao, A., Hollis, W., Huber, G., Scherle, R., Ruggeri, P., Liu, B.P., Lee, S.H., Combination of BET inhibitor INC and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo. Cancer Res., AM2016-4702, 2016, B054329, 10.1158/1538-7445.
68. Lopez-Soto, A., Folgueras, A.R., Seto, E., Gonzalez, S., HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28 (2009), 2370–2382.
69. Lucarini, V., Buccione, C., Ziccheddu, G., Peschiaroli, F., Sestili, P., Puglisi, R., Mattia, G., Zanetti, C., Parolini, I., Bracci, L., Macchia, I., Rossi, A., D'Urso, M.T., Macchia, D., Spada, M., De Ninno, A., Gerardino, A., Mozetic, P., Trombetta, M., Rainer, A., Businaro, L., Schiavoni, G., Mattei, F., Combining type I interferons and 5-Aza-2’-Deoxycitidine to improve anti-tumor response against melanoma. J. Invest. Dermatol. 137 (2017), 159–169.
70. Lundqvist, A., Abrams, S.I., Schrump, D.S., Alvarez, G., Suffredini, D., Berg, M., Childs, R., Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66 (2006), 7317–7325.
71. Luo, W., Wang, X., Kageshita, T., Wakasugi, S., Karpf, A.R., Ferrone, S., Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25 (2006), 2873–2884.
72. Macfarlan, T.S., Gifford, W.D., Agarwal, S., Driscoll, S., Lettieri, K., Wang, J., Andrews, S.E., Franco, L., Rosenfeld, M.G., Ren, B., Pfaff, S.L., Endogenous retroviruses and neighboring genes are coordinately repressed by LSD1/KDM1A. Genes Dev. 25 (2011), 594–607.
73. Maeda, T., Towatari, M., Kosugi, H., Saito, H., Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96 (2000), 3847–3856.
74. Mager, D.L., Stoye, J.P., Mammalian endogenous retroviruses. Microbiol. Spectr., 3, 2015 (MDNA3-0009-2014).
75. Magner, W.J., Kazim, A.L., Stewart, C., Romano, M.A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., Tomasi, T.B., Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165 (2000), 7017–7024.
76. Maio, M., Covre, A., Fratta, E., Di Giacomo, A.M., Taverna, P., Natali, P.G., Coral, S., Sigalotti, L., Molecular pathways At the crossroads of cancer epigenetics and immunotherapy. Clin. Cancer Res. 21 (2015), 4040–4047.
77. Markham, A., Atezolizumab first global approval. Drugs 76 (2016), 1227–1232.
78. Martinez-Outschoorn, U.E., Pavlides, S., Whitaker-Menezes, D., Daumer, K.M., Milliman, J.N., Chiavarina, B., Migneco, G., Witkiewicz, A.K., Martinez-Cantarin, M.P., Flomenberg, N., Howell, A., Pestell, R.G., Lisanti, M.P., Sotgia, F., Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9 (2010), 2423–2433.
79. Mikyskova, R., Indrova, M., Vlkova, V., Bieblova, J., Simova, J., Parackova, Z., Pajtasz-Piasecka, E., Rossowska, J., Reinis, M., DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J. Leukoc. Biol. 95 (2014), 743–753.
80. Minn, A.J., Wherry, E.J., Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165 (2016), 272–275.
81. Minn, A.J., Interferons and the immunogenic effects of cancer therapy. Trends Immunol. 36 (2015), 725–737.
82. Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., Sakai, T., Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23 (2004), 6261–6271.
83. Nishikawa, H., Sakaguchi, S., Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27 (2014), 1–7.
84. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
85. Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, S.V., Linsley, P.S., Thompson, C.B., Riley, J.L., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25 (2005), 9543–9553.
86. Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., Zou, W., Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
87. Petersen, R.P., Campa, M.J., Sperlazza, J., Conlon, D., Joshi, M.B., Harpole, D.H. Jr., Patz, E.F. Jr., Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006), 2866–2872.
88. Raulet, D.H., Gasser, S., Gowen, B.G., Deng, W., Jung, H., Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31 (2013), 413–441.
89. Roulois, D., Blanquart, C., Panterne, C., Gueugnon, F., Gregoire, M., Fonteneau, J.F., Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur. J. Immunol. 42 (2012), 783–789.
90. Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S.Y., Han, H., Liang, G., Jones, P.A., Pugh, T.J., O'Brien, C., De Carvalho, D.D., DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162 (2015), 961–973.
91. Sahakian, E., Powers, J.J., Chen, J., Deng, S.L., Cheng, F., Distler, A., Woods, D.M., Rock-Klotz, J., Sodre, A.L., Youn, J.I., Woan, K.V., Villagra, A., Gabrilovich, D., Sotomayor, E.M., Pinilla-Ibarz, J., Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol. Immunol. 63 (2015), 579–585.
92. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., Iacopetta, B., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27 (2009), 186–192.
93. Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J.F., Moretta, L., Broker, B.M., Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 272 (2008), 110–121.
94. Schneider, R., Grosschedl, R., Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev. 21 (2007), 3027–3043.
95. Setiadi, A.F., Omilusik, K., David, M.D., Seipp, R.P., Hartikainen, J., Gopaul, R., Choi, K.B., Jefferies, W.A., Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 68 (2008), 9601–9607.
96. Sheppard, K.A., Fitz, L.J., Lee, J.M., Benander, C., George, J.A., Wooters, J., Qiu, Y., Jussif, J.M., Carter, L.L., Wood, C.R., Chaudhary, D., PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574 (2004), 37–41.
97. Shi, W., Li, X., Cha, Z., Sun, S., Wang, L., Jiao, S., Yang, B., Shi, Y., Wang, Z., Wu, Z., Dai, G., Dysregulation of circulating follicular helper T cells in nonsmall cell lung cancer. DNA Cell Biol. 33 (2014), 355–360.
98. Sica, A., Schioppa, T., Mantovani, A., Allavena, P., Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42 (2006), 717–727.
99. Sigalotti, L., Fratta, E., Coral, S., Maio, M., Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol. Ther. 142 (2014), 339–350.
100. Skov, S., Pedersen, M.T., Andresen, L., Straten, P.T., Woetmann, A., Odum, N., Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65 (2005), 11136–11145.
101. Smyth, M.J., Teng, M.W., Swann, J., Kyparissoudis, K., Godfrey, D.I., Hayakawa, Y., CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176 (2006), 1582–1587.
102. Soon, P.S., Kim, E., Pon, C.K., Gill, A.J., Moore, K., Spillane, A.J., Benn, D.E., Baxter, R.C., Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr. Relat. Cancer 20 (2013), 1–12.
103. Stengel, S., Fiebig, U., Kurth, R., Denner, J., Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes. Chromosomes Cancer 49 (2010), 401–411.
104. Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R., Melief, C.J., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001), 823–832.
105. Taddei, A., Maison, C., Roche, D., Almouzni, G., Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 3 (2001), 114–120.
106. Tang, Y., Xu, X., Guo, S., Zhang, C., Tang, Y., Tian, Y., Ni, B., Lu, B., Wang, H., An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One, 9, 2014, e91551.
107. Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
108. Tellez, C.S., Grimes, M.J., Picchi, M.A., Liu, Y., March, T.H., Reed, M.D., Oganesian, A., Taverna, P., Belinsky, S.A., SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int. J. Cancer 135 (2014), 2223–2231.
109. Terracina, K.P., Graham, L.J., Payne, K.K., Manjili, M.H., Baek, A., Damle, S.R., Bear, H.D., DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol. Immunother. 65 (2016), 1061–1073.
110. Terranova-Barberio, M., Thomas, S., Munster, P.N., Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 8 (2016), 705–719.
111. Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., Lawrence, D.P., Atkins, M.B., Powderly, J.D., Leming, P.D., Lipson, E.J., Puzanov, I., Smith, D.C., Taube, J.M., Wigginton, J.M., Kollia, G.D., Gupta, A., Pardoll, D.M., Sosman, J.A., Hodi, F.S., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
112. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., Herati, R.S., Mansfield, K.D., Patsch, D., Amaravadi, R.K., Schuchter, L.M., Ishwaran, H., Mick, R., Pryma, D.A., Xu, X., Feldman, M.D., Gangadhar, T.C., Hahn, S.M., Wherry, E.J., Vonderheide, R.H., Minn, A.J., Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
113. Tyan, S.W., Kuo, W.H., Huang, C.K., Pan, C.C., Shew, J.Y., Chang, K.J., Lee, E.Y., Lee, W.H., Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One, 6, 2011, e15313.
114. Usami, Y., Ishida, K., Sato, S., Kishino, M., Kiryu, M., Ogawa, Y., Okura, M., Fukuda, Y., Toyosawa, S., Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int. J. Cancer 133 (2013), 568–578.
115. Vitale, M., Rezzani, R., Rodella, L., Zauli, G., Grigolato, P., Cadei, M., Hicklin, D.J., Ferrone, S., HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58 (1998), 737–742.
116. Waldhauer, I., Steinle, A., NK cells and cancer immunosurveillance. Oncogene 27 (2008), 5932–5943.
117. Wang, L.X., Mei, Z.Y., Zhou, J.H., Yao, Y.S., Li, Y.H., Xu, Y.H., Li, J.X., Gao, X.N., Zhou, M.H., Jiang, M.M., Gao, L., Ding, Y., Lu, X.C., Shi, J.L., Luo, X.F., Wang, J., Wang, L.L., Qu, C., Bai, X.F., Yu, L., Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One, 8, 2013, e62924.
118. Wang, L., Amoozgar, Z., Huang, J., Saleh, M.H., Xing, D., Orsulic, S., Goldberg, M.S., Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunol Res 3 (2015), 1030–1041.
119. Weber, J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J., Rosenberg, S.A., Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 54 (1994), 1766–1771.
120. Weintraub, K., Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat. Med. 22 (2016), 8–10.
121. Weiser, T.S., Ohnmacht, G.A., Guo, Z.S., Fischette, M.R., Chen, G.A., Hong, J.A., Nguyen, D.M., Schrump, D.S., Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thorac. Surg. 71 (2001), 295–301 discussion 301-292.
122. Wischnewski, F., Pantel, K., Schwarzenbach, H., Promoter demethylation and histone acetylation mediate gene expression of MAGE −A1, −A2, −A3, and −A12 in human cancer cells. Mol. Cancer Res. 4 (2006), 339–349.
123. Wolf, D., Wolf, A.M., Rumpold, H., Fiegl, H., Zeimet, A.G., Muller-Holzner, E., Deibl, M., Gastl, G., Gunsilius, E., Marth, C., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005), 8326–8331.
124. Woods, D.M., Sodre, A.L., Villagra, A., Sarnaik, A., Sotomayor, E.M., Weber, J., HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res. 3 (2015), 1375–1385.
125. Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendetti, F., Vancriekinge, W., Demeyer, T., Du, Z., Parsana, P., Rodgers, K., Yen, R.W., Zahnow, C.A., Taube, J.M., Brahmer, J.R., Tykodi, S.S., Easton, K., Carvajal, R.D., Jones, P.A., Laird, P.W., Weisenberger, D.J., Tsai, S., Juergens, R.A., Topalian, S.L., Rudin, C.M., Brock, M.V., Pardoll, D., Baylin, S.B., Alterations of immune response of non-Small cell lung cancer with azacytidine. Oncotarget 4 (2013), 2067–2079.
126. Xu, P., Hu, G., Luo, C., Liang, Z., DNA methyltransferase inhibitors: an updated patent review (2012–2015). Expert Opin. Ther. Pat. 26 (2016), 1017–1030.
127. Yamanegi, K., Yamane, J., Kobayashi, K., Kato-Kogoe, N., Ohyama, H., Nakasho, K., Yamada, N., Hata, M., Fukunaga, S., Futani, H., Okamura, H., Terada, N., Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Int. J. Oncol. 41 (2012), 83–91.
128. Yang, D., Torres, C.M., Bardhan, K., Zimmerman, M., McGaha, T.L., Liu, K., Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J. Immunol. 188 (2012), 4441–4449.
129. Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M.R., Davanlou, M., Geng, Q.R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., Parmar, S., Cortes, J., Kantarjian, H., Garcia-Manero, G., Expression of PD-L1, PD-L2 PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28 (2014), 1280–1288.
130. Yao, Y., Zhou, J., Wang, L., Gao, X., Ning, Q., Jiang, M., Wang, J., Wang, L., Yu, L., Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One, 8, 2013, e70522.
131. Yoder, J.A., Walsh, C.P., Bestor, T.H., Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13 (1997), 335–340.
132. Yu, Y., Xiao, C.H., Tan, L.D., Wang, Q.S., Li, X.Q., Feng, Y.M., Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br. J. Cancer 110 (2014), 724–732.
133. Zeng, M., Hu, Z., Shi, X., Li, X., Zhan, X., Li, X.D., Wang, J., Choi, J.H., Wang, K.W., Purrington, T., Tang, M., Fina, M., DeBerardinis, R.J., Moresco, E.M., Pedersen, G., McInerney, G.M., Karlsson Hedestam, G.B., Chen, Z.J., Beutler, B., MAVS, cGAS, and endogenous retroviruses in T-independent B cell responses. Science 346 (2014), 1486–1492.
134. Zhang, C., Wang, S., Liu, Y., Yang, C., Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. Oncotarget 7 (2016), 57452–57463.
135. Zheng, H., Zhao, W., Yan, C., Watson, C.C., Massengill, M., Xie, M., Massengill, C., Noyes, D.R., Martinez, G.V., Afzal, R., Chen, Z., Ren, X., Antonia, S.J., Haura, E.B., Ruffell, B., Beg, A.A., HDAC inhibitors enhance T-Cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 4119–4132.
136. Zhu, S., Denman, C.J., Cobanoglu, Z.S., Kiany, S., Lau, C.C., Gottschalk, S.M., Hughes, D.P., Kleinerman, E.S., Lee, D.A., The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm. Res. 32 (2015), 779–792.
137. Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M.R., Bitler, B.G., Allegrezza, M.J., Yokoyama, Y., Kossenkov, A.V., Bradner, J.E., Conejo-Garcia, J.R., Zhang, R., BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 16 (2016), 2829–2837.
138. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.